ArticleAdvances in therapy2025

Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.